Contract Pharma2h
OliX, Lilly Enter Global Licensing Agreement for Cardiometabolic Indications
To develop OliX’s OLX75016 candidate primarily targeting metabolic-associated steatohepatitis (MASH).
Hosted on MSN21h
Eli Lilly pledges $630m on OliX’s Phase I RNA candidate for MASH
Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.
BioSpace7h
New M&A Action, BMS’ Ongoing Cost Cuts and the Insatiable Demand for Weight Loss Drugs
Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, sales continue to soar for Lilly and Novo Nordisk’s GLP-1s and Regeneron ...
A Promising Development for Millions of People With Liver Disease
Recent research suggests that a new approach could help even patients with advanced forms of fatty liver disease.